Sunday 18 October 2026
Export EYPT’s income statement to Excel — free account
EyePoint, Inc.
EYPT Healthcare Biotechnology
EyePoint, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.4 million, down 27.5% from fiscal 2024. In the quarter to June 2026, revenue fell 90.5%, EPS fell 28.2% and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.00
0.14
−4.46%
Follow EYPT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
23.60 | 42.66 | 145.59 | 443.89 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(16.83) | (20.57) | (13.76) | (19.85) | |
P/B ratio |
4.99 | 4.37 | 4.81 | 7.44 | |
Price to Tangible BV |
5.57 | 4.69 | 5.29 | 8.51 | |
EV/Sales |
19.60 | 34.01 | 120.92 | 391.59 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.93) | (4.44) | (3.44) | (4.08) | |
EV/FCF |
(3.89) | (4.39) | (3.39) | (4.03) | |
Quick Ratio |
6.81 | 8.28 | 5.97 | 4.30 | |
Current Ratio |
7.18 | 8.88 | 6.66 | 4.50 | |
Net Debt/EBITDA |
3.27 | 4.34 | 2.55 | 1.86 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.15 | 0.08 | 0.02 | 0.01 | |
Operating CF/Net income |
0.99 | 0.96 | 0.95 | 0.66 | |
Capex/Depreciation |
2.13 | 3.39 | 7.02 | (2.40) | |
Research and Development Expense of Revenue |
4,943.48% | 9,565.91% | 10,366.09% | 16,491.91% | |
Selling, General and Administrative Expense of Revenue |
1,502.69% | 1,837.80% | 2,190.52% | 2,815.19% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
665.42% | 1,090.31% | 1,672.13% | 2,050.89% | |
Graham Net Nets |
0.16 | 0.20 | 0.17 | 0.10 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(21.00%) | (17.30%) | (27.15%) | (26.15%) | |
Free Cash Flow Yield |
(21.38%) | (18.17%) | (24.48%) | (21.91%) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.85) | (0.89) | (0.94) | (0.72) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.86) | (0.90) | (0.95) | (0.73) | |
Cash per Share |
2.91 | 4.18 | 2.59 | 2.09 | |
Shareholders Equity per Share |
2.85 | 4.18 | 2.68 | 1.92 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.85 | 4.18 | 2.68 | 1.92 | |
Free Cash Flow |
(60.15) | (65.88) | (81.55) | (63.55) | |
Working Capital |
186.01 | 291.63 | 212.04 | 146.87 | |
Capital Expenditures |
(0.80) | (0.83) | (1.00) | (1.20) | |
Net Current Asset Value |
164.59 | 270.77 | 191.76 | 127.04 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.83 | 1.34 | 1.43 | 2.37 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.71 | 0.63 | 0.80 | 0.36 | |
Average Payables |
8.71 | 11.11 | 17.62 | 18.48 | |
Average Inventory |
2.46 | 2.06 | 1.69 | 2.28 | |
Average Assets |
276.31 | 391.23 | 325.39 | 264.67 | |
Average Common Equity |
209.46 | 321.31 | 264.43 | 206.21 |
Columns are period end dates